RxDoctor Payments Data

Kaushik Annam, MD

Ophthalmology · Ann Arbor, MINPI 1518529650

Payments from drug & device makers

$3,667in general payments, 2019–2025

Across 53 payments — averaging $69.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • AbbVie$678
  • Sight Sciences, Inc.$369
  • Apellis Pharmaceuticals, Inc.$199
  • E.r. Squibb & Sons, L.L.C.$125
  • Tarsus Pharmaceuticals, Inc.$120
  • plus $353 from 7 others

What the payments were for

  • Travel & lodging$98227%
  • Food & beverage$2,58570%
  • Education$1003%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,667 in reported general payments places this provider in the 75th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$16,303
Medicare patients
90
Services billed
204

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate104$39,509
LumiganBimatoprost57$22,089
RocklatanNetarsudil Mesylat/Latanoprost28$20,591
Brimonidine Tartrate264$18,165
VyzultaLatanoprostene Bunod37$15,813
Latanoprost528$10,804
SimbrinzaBrinzolamide/Brimonidine Tart40$10,108
TafluprostTafluprost/Pf49$9,309
Dorzolamide-TimololDorzolamide/Timolol/Pf72$8,787
Timolol Maleate212$8,078
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat274$7,997
Methazolamide22$6,855
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol23$6,814
CombiganBrimonidine Tartrate/Timolol13$6,362
Prednisolone Acetate179$6,202

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Alphagan P$678$34,54881 claims
Bausch & Lomb Americas Inc.Vyzulta$38$15,81337 claims
AlconSimbrinza$1,823$10,10840 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Ann Arbor

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →